Novo Nordisk's Semaglutide Pill Lowers Blood Sugar of Children, Adolescents with Diabetes in Phase 3a Study
Idag, 12:37
06:37 AM EDT, 04/23/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) said Thursday that oral semaglutide helped lower the blood sugar of children and adolescents with type 2 diabetes in its phase 3a trial called Pioneer Teens.
Results of the clinical study showed that the semaglutide pill reduced the HbA1c levels of trial participants, aged 10 to 17 years, by 0.83% after 26 weeks. Novo Nordisk said the reduction is statistically significant and superior compared with placebo.
The Danish drugmaker plans to seek regulatory approval to expand the label for the Ozempic pill and Rybelsus in the US and the European Union in the second half of 2026.
Ämnen i artikeln
Novo Nordisk's Semaglutide Pill Lowers Blood Sugar of Children, Adolescents with Diabetes in Phase 3a Study
Idag, 12:37
06:37 AM EDT, 04/23/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) said Thursday that oral semaglutide helped lower the blood sugar of children and adolescents with type 2 diabetes in its phase 3a trial called Pioneer Teens.
Results of the clinical study showed that the semaglutide pill reduced the HbA1c levels of trial participants, aged 10 to 17 years, by 0.83% after 26 weeks. Novo Nordisk said the reduction is statistically significant and superior compared with placebo.
The Danish drugmaker plans to seek regulatory approval to expand the label for the Ozempic pill and Rybelsus in the US and the European Union in the second half of 2026.
Ämnen i artikeln
Rapporter
Analys
-160x160.jpg&w=3840&q=75)
